Watermark
  Back to Search Results

AdvanTIG-204

Completed

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

BeOne Study ID Info icon SVG graphic used for tooltips or additional information.

AdvanTIG-204

ClinicalTrials.gov ID Info icon SVG graphic used for tooltips or additional information.

NCT04952597

China Drug Trials ID Info icon SVG graphic used for tooltips or additional information.

CTR20211531

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan